CClinicalTrials.gg
CompletedNCT03344107Updated Dec 1, 2020

Stent-related Symptoms Comparison: Polaris Loop vs Vortek Double-J Stents

An interventional study of USSQ questionnaire administration after RIRS. in Symptoms and Signs, Pain and Renal Calculi, sponsored by A.O.U. Città della Salute e della Scienza. Completed at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-12-01.

Sponsored by A.O.U. Città della Salute e della Scienza · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Prospective randomized controlled single-blind parallel-group trial in order to compare symptoms related to loop-tail (Polaris Loop) stents versus conventional double J (Vortek) stents after uncomplicated flexible URS.

Read the detailed description

Patients undergoing RIRS for a single renal stone \< 2 cm are asked to participate in a prospective randomized controlled single-blind parallel-group study. Ureteral stent is always placed after flexible URS. Patients are prospectively randomized into two groups with a 1:1 allocation: group LT receive loop-tail stents (Polaris ™ Loop - Boston Scientific, Natick, USA), while group DJ receive conventional double J stents (Vortek ® - Coloplast, Humlebaek, DK). Stent removal is planned 4 weeks after the procedure.

Participants are asked to fill in the Italian validated version of the Ureteral Stent Symptoms Questionnaire (USSQ) 2 days and 4 weeks after surgery. The USSQ is further submitted 4 weeks after stent removal (8 weeks after surgery) and these results are used as baseline evaluation, on the assumption that SRS persist for a few days after removal.

02

Conditions studied

  • Symptoms and Signs
  • Pain
  • Renal Calculi

Keywords

  • Symptoms and Signs
  • Pain
  • Renal Calculi
  • Ureteral Stent
  • Ureteroscopy
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • patients undergoing flexible ureteroscopy and laser lithotripsy for kidney stones \< 2 cm
  • given informed consent
  • WHO PS 0-2

Exclusion criteria

Exclusion Criteria:

  • significant residual fragments at the end of the procedure
  • intraoperative complications (i.e. ureteral damage or ureteral stricture)
  • urinary tract infections
  • anatomic abnormalities
  • chronic diseases or medications potentially influencing pain perception and urinary symptoms (i.e. alpha blockers and antimuscarinics)
  • preoperative ureteral stenting.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
68 participants (actual)

Study arms

  • Active comparator
    Vortek double-J stent

    Vortek double-J stent after RIRS.

    Other: USSQ questionnaire administration after RIRS.

  • Active comparator
    Polaris Loop stent

    Polaris Loop ureteral stent after RIRS.

    Other: USSQ questionnaire administration after RIRS.

Interventions

  • OtherUSSQ questionnaire administration after RIRS.

    USSQ symptoms questionnaire administration after RIRS

05

What researchers measure

Primary outcomes

  1. USSQ Urinary symptoms scores

    Evaluation of significant differences in Urinary symptoms score between the two groups

    Time frame: 4 weeks

Secondary outcomes

  1. USSQ domains scores

    Evaluation of significant differences in USSQ domains' scores between the two groups

    Time frame: 4 weeks

  2. USSQ domains scores

    Evaluation of significant differences in USSQ domains' scores between the two groups

    Time frame: 2 days

  3. USSQ domains' scores adjusted for baseline

    Evaluation of significant differences in USSQ domains' scores adjusted for baseline between the two groups

    Time frame: 8 weeks

06

Study locations

1 site
  • AOU Città della Salute e della Scienza
    Torino, 10126, Italy
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03344107
Lead sponsor
A.O.U. Città della Salute e della Scienza
Responsible party
Andrea Bosio (MD Urologist, PhD, A.O.U. Città della Salute e della Scienza) — Principal investigator
First posted
Nov 17, 2017
Start date
Jan 10, 2018
Primary completion
Feb 13, 2020
Completion
Apr 17, 2020
Last update
Dec 1, 2020

Study contacts

Andrea Bosio, MD
principal investigator · AOU Città della Salute e della Scienza, Torino

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion